EDCL’s monopoly fetches ultra-profit from lifesaving injections

The government drug manufacturing company EDCL is allegedly exploiting its monopoly over the public hospitals to raise the price of antibiotic injections, charging double or three times more than what is charged by other pharmaceuticals.

According to public rule, if any medicine or injection is available in the Essential Drug Company Limited (EDCL) list, public hospitals must purchase the items from the EDCL without floating any tender.

Although the lifesaving injections were not originally on the list of EDCL-produced medicines, the state-run company is currently producing injections like Ceftriazone, Ceftazidime, Cefuroxime and Cepharadine. 

As the hospitals have no other choice but to buy these injections from the EDCL at higher prices, they often do not have adequate funds to buy the required number of drugs to meet the demand, and so patients are being forced to buy injections from pharmacies.

During the last fiscal year, most public medical college hospitals bought 70% of their drugs from the EDCL and the rest from other pharmaceuticals through the competitive tender process.

However, the EDCL is now getting a bigger market share from the public hospitals after it began producing medicines that were not previously on its list. The government-owned company is also charging extra for the new items.

Brig Gen Dr Mustafizur Rahman, director of the Dhaka Medical College Hospital, admitted that the cost of commonly used antibiotic injections had seen a rapid increase, adding that the hospital was unable to buy enough injections compared to the previous year.

“We have to spend most of the money allotted for MSR [medicine and surgical reagent] to pay the EDCL bill. But we are trying our best to continue to supply antibiotics to the patients, free of cost,” he added.

When asked about the issue, Ratan Kumar, secretary of EDCL, refused to comment and instead referred to the DGM of sales for further inquiries. However, the DGM, Abul Kashem Patwary, could not be reached for comments despite repeated attempts.

Ceftriazone – one of the most common antibiotic injections being used at the hospitals – was bought earlier by the DMCH at Tk26, Tk34 and Tk68 for each vial containing 500mg, 1g and 2g of the drug, respectively. Tender process was used to buy over 50,000 vials of Ceftriazone every month from private pharmaceuticals.  However, the same vials are now being bought from the EDCL for Tk98, Tk115 and Tk175, respectively.

The 500mg and 1g vials of Ceftazidime – mostly used for treating burn patients - were bought earlier by the DMCH from private pharmaceuticals for Tk40.65 and Tk64.5, respectively; the EDCL prices for the same vials are Tk85 and Tk150.

Last year, market prices for the 750mg and 1.5g vials of the antibiotic injection Cefuroxime (ram) were Tk40.4 and Tk69.94; but the EDCL is currently charging Tk100 and Tk150 for the same vials.

Sephradine (500 mg) was bought for Tk18.30 whereas as the EDCL is currently charging Tk60 per vial.